Invention Grant
- Patent Title: Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles
-
Application No.: US15986577Application Date: 2018-05-22
-
Publication No.: US10656162B2Publication Date: 2020-05-19
- Inventor: Heidi Alexandra Lane , Felix Bachmann
- Applicant: Basilea Pharmaceutica AG
- Applicant Address: CH Basel
- Assignee: Basilea Pharmaceutica AG
- Current Assignee: Basilea Pharmaceutica AG
- Current Assignee Address: CH Basel
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@68caeefa
- Main IPC: A61K31/4245
- IPC: A61K31/4245 ; G01N33/50 ; G01N33/68
Abstract:
Use of glu-tubulin as a biomarker for predicting the response to a compound, preferably resistance of a disease such as cancer in a subject to said compound, wherein the compound is a furazanobenzimidazole compound of general formula (I).
Public/Granted literature
- US20180364254A1 USE OF GLU-TUBULIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES Public/Granted day:2018-12-20
Information query
